Ekso Bionics (NASDAQ:EKSO) Releases Earnings Results, Misses Expectations By $0.02 EPS

Ekso Bionics (NASDAQ:EKSO) posted its quarterly earnings results on Monday. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02), Yahoo Finance reports. Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The business had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. During the same period in the prior year, the business posted ($0.24) earnings per share.

Ekso Bionics Stock Performance

NASDAQ:EKSO opened at $0.96 on Wednesday. The company’s 50-day moving average is $1.11 and its two-hundred day moving average is $1.15. The firm has a market capitalization of $17.45 million, a price-to-earnings ratio of -0.99 and a beta of 1.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.42 and a quick ratio of 1.77. Ekso Bionics has a 1-year low of $0.83 and a 1-year high of $3.13.

Analysts Set New Price Targets

A number of research firms have commented on EKSO. StockNews.com initiated coverage on shares of Ekso Bionics in a report on Saturday. They issued a “hold” rating for the company. Lake Street Capital reduced their price objective on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, HC Wainwright dropped their target price on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.